Phase 2 N=147 Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
Breast Cancer
Primary: Best Overall Response — 1; 0; 1; 12 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=13 Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Number of Participants With Response (Complete Response or Progressive Disease) — 2; 6 Participants
Phase 2 N=334 A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Probability of Participants With Sustained Accumulation of Disability (SAD) — 0.27; 0.08; 0.09; 0.09 probability of participants with SAD — p=0.0006
Phase 2 N=27 A Trial for Patients With Advanced/Recurrent Endometrial Cancer
Neoplasms · Neoplasms by Site · Urogenital Neoplasms
Primary: Tumor Response — 0; 1; 12; 11 participants
Phase 2 N=29 A Trial for Patients With Advanced/Recurrent Cervical Cancer
Cervical Intraepithelial Neoplasia · Uterine Neoplasms · Genital Neoplasms, Female
Primary: Tumor Response — 0; 4; 16; 7 participants
Phase 2 N=51 A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer
Ovarian Cancer · Peritoneal Cancer
Primary: Tumor Response — 1; 9; 17; 18 participants
Phase 2 N=82 Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis
Deep Vein Thrombosis
Primary: To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT — 76.9; 65.4; 100; 96.2 % Specificity
Phase 2 N=74 Glucose Regulation in Acute Stroke Patients (GRASP) Study
Stroke · Hyperglycemia
Primary: Hypoglycemic Events — 7; 1; 1 participants
Phase 2 N=266 Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne
Acne Vulgaris
Primary: Change in Inflammatory Lesion Counts Relative to Baseline — -18.0; -14.0; -19.0; -14.5 change in lesion count — p=0.7680
Phase 2 N=52 Lapatinib and Bevacizumab for Metastatic Breast Cancer
Neoplasms, Breast
Primary: Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment — 36; 16 Participants
Phase 2 N=70 Combination Chemotherapy for Metastatic Breast Cancer
Breast Cancer
Primary: Objective Tumor Response — 7; 19; 19; 5 participants
Phase 2 N=24 Fermented Milk Drink on Human Intestinal Microflora
Signs and Symptoms, Digestive
Primary: Modification of the Composition of the Intestinal Microflora: Bifidobacterium — 7.88; 7.60; 8.13; 8.10 log10 CFU/g — p=<0.05
Phase 2 N=269 Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9) — 37; 20 Participants
Phase 2 N=113 Natalizumab High Titer Immunogenicity and Safety
Multiple Sclerosis
Primary: Number of Participants With Anti-Natalizumab Antibody Negative, Transient Positive, and Persistent Positive Status — 96; 3; 9 participants
Phase 2 N=54 A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
Drooling
Primary: Change in Drooling Frequency & Severity Scale (DFSS)at Wk 4 Post-injection — -2.1; -3.3; -3.5; -1.3 points on a scale